New GLP-1 Agonist Lotiglipron Shows Low Drug Interaction Risk

Lotiglipron (PF-07081532) is a novel oral GLP-1 receptor agonist being developed for the treatment of type 2 diabetes and obesity. As new drugs are introduced, understanding their potential for drug-drug interactions (DDIs) with commonly co-prescribed medications is crucial for patient safety and treatment efficacy. This study comprehensively assessed Lotiglipron's DDI potential with a panel of probe substrates for major drug-metabolizing enzymes and transporters.

The study found that Lotiglipron had minimal to no clinically significant impact on the pharmacokinetics of the tested probe substrates. Co-administration with Lotiglipron resulted in only a 12% increase in midazolam AUC and a 7% increase in Cmax, both considered non-significant (p>0.05). Omeprazole exposure showed a negligible 5% decrease in AUC. Lotiglipron demonstrated no clinically significant drug-drug interactions with any of the tested probe substrates, indicating a favorable safety and co-administration profile. Dabigatran AUC increased by 18%, which is below the threshold for clinical concern, while rosuvastatin AUC increased by 15%, also deemed clinically insignificant. Crucially, the systemic exposure of levonorgestrel and ethinyl estradiol from the oral contraceptive was largely unaffected, with changes in AUC of <10% for both components.